Aurobindo Pharma stock: Q2 profit rises 32.5% on record revenue

Aurobindo Pharma reported a sharp rise in second-quarter earnings on November 4, 2026, with consolidated net profit up 32.5% year on year to INR 1,124 crore. Revenue increased 24% to INR 10,263 crore, the company's highest quarterly level, according to The Hindu BusinessLine.

Record revenue sets the tone

The result covers the quarter ended September 30, 2026. Revenue rose from INR 8,286 crore in the year-ago quarter, while net profit increased from INR 848 crore. The scale of the revenue increase points to broad-based expansion across Aurobindo Pharma's operations rather than a single reported product event.

Vice-Chairman and Managing Director K. Nithyananda Reddy said the performance reflected business fundamentals, sustained execution and the resilience of the company's diversified product portfolio. He also pointed to organic momentum and the integration of inorganic opportunities as the company advances its strategic priorities.

What investors will watch next

For investors, the next focus is whether the stronger quarterly base can be sustained across the company's international and domestic activities. Execution, product mix and the contribution from recently integrated businesses will shape how much of the second-quarter improvement carries into the second half of the financial year.

Broader Indian market coverage is available in the BSE Sensex market topic.

More news and analyses on Aurobindo Pharma stock.